Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00663143 · ClinicalTrials.gov registry record
Thiazolidinediones (TZD) Bone Loss and the Effects on Bone Marrow Differentiation and Osteoblast Formation
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 9
- Enrollment target
NCT00663143 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 9 participants.
The verdict
NCT00663143 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
Thiazolidinediones (TZDs) are a commonly used antidiabetic drugs currently used by over a million patients in the United States. Recent studies have shown that treatment with TZD may increase the risk of bone fractures. The cause of bone loss is not known. We believe that TZD may cause increased accumulation of fat in the bone marrow, which may cause decrease bone formation and weak bones. .
Interventions
- PROCEDURE Stromal Cells Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00663143
The ClinicalTrials.gov registry entry for NCT00663143 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stromal Cells Sample is the first listed.
NCT00663143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00663143 about?
NCT00663143 is a clinical study titled "Thiazolidinediones (TZD) Bone Loss and the Effects on Bone Marrow Differentiation and Osteoblast Formation". Thiazolidinediones (TZDs) are a commonly used antidiabetic drugs currently used by over a million patients in the United States. Recent studies have shown that treatment with TZD may increase the risk of bone fractures. The cause of bone loss is not known. We believe that TZD may cause increased acc...
What is the current status of trial NCT00663143?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2009-07. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00663143?
The interventions under investigation include: Stromal Cells Sample (PROCEDURE).
Who is sponsoring clinical trial NCT00663143?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.